Clinical Trials | October 25, 2025
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Subscribe To Our Newsletter & Stay Updated
